Maximus (NYSE:MMS) Stock Rating Lowered by Wall Street Zen

Maximus (NYSE:MMS) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Monday.

Several other analysts also recently weighed in on MMS. Zacks Research upgraded shares of Maximus from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 30th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Maximus in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Strong Buy”.

Maximus Trading Up 1.2%

NYSE MMS opened at $73.27 on Monday. The company has a market capitalization of $4.00 billion, a price-to-earnings ratio of 11.15 and a beta of 0.57. The company’s fifty day moving average price is $87.57 and its two-hundred day moving average price is $86.58. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.34 and a quick ratio of 2.34. Maximus has a 12 month low of $63.77 and a 12 month high of $100.00.

Maximus (NYSE:MMS) last posted its quarterly earnings results on Thursday, February 5th. The health services provider reported $1.85 EPS for the quarter, beating the consensus estimate of $1.84 by $0.01. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.37 billion. Maximus had a net margin of 6.92% and a return on equity of 25.30%. The company’s quarterly revenue was down 4.1% on a year-over-year basis. During the same period in the previous year, the business posted $1.61 EPS. Maximus has set its FY 2026 guidance at 8.050-8.350 EPS. As a group, research analysts predict that Maximus will post 6.15 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Michelle F. Link sold 4,039 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $86.84, for a total transaction of $350,746.76. Following the completion of the sale, the insider directly owned 19,542 shares of the company’s stock, valued at $1,697,027.28. This represents a 17.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO David Mutryn purchased 1,000 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was acquired at an average price of $75.62 per share, for a total transaction of $75,620.00. Following the transaction, the chief financial officer owned 40,037 shares of the company’s stock, valued at $3,027,597.94. The trade was a 2.56% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have acquired 4,231 shares of company stock worth $329,521. 1.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Maximus

Several large investors have recently modified their holdings of the stock. Royal Bank of Canada raised its position in shares of Maximus by 146.2% during the first quarter. Royal Bank of Canada now owns 19,732 shares of the health services provider’s stock worth $1,345,000 after purchasing an additional 11,716 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Maximus by 0.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,476 shares of the health services provider’s stock worth $2,351,000 after buying an additional 221 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Maximus by 7.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 180,690 shares of the health services provider’s stock worth $12,321,000 after buying an additional 11,754 shares during the period. Jane Street Group LLC boosted its holdings in shares of Maximus by 941.2% in the first quarter. Jane Street Group LLC now owns 98,273 shares of the health services provider’s stock worth $6,701,000 after buying an additional 88,835 shares during the period. Finally, Sivia Capital Partners LLC acquired a new position in shares of Maximus in the second quarter worth about $204,000. 97.21% of the stock is owned by institutional investors.

About Maximus

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.